Holen Sie sich die Stockscreener-App
1.63
11.44%
-0.25
Handel nachbörslich:
1.63
Schlusskurs vom Vortag:
$1.88
Offen:
$1.78
24-Stunden-Volumen:
9.20M
Relative Volume:
1.51
Marktkapitalisierung:
$195.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-225.14M
KGV:
-0.8316
EPS:
-1.96
Netto-Cashflow:
$-192.27M
1W Leistung:
+2.15%
1M Leistung:
+16.43%
6M Leistung:
+217.08%
1J Leistung:
+67.56%
1-Tages-Spanne:
$1.56
$1.84
1-Wochen-Bereich:
$1.56
$2.01
52-Wochen-Spanne:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Firmenname
Invivyd Inc
Sektor
Branche
Telefon
(781) 819-0080
Adresse
1601 TRAPELO ROAD, WALTHAM
Vergleichen Sie IVVD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.63 | 403.09M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-04-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-26 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Eingeleitet | H.C. Wainwright | Buy |
Invivyd Inc Aktie (IVVD) Neueste Nachrichten
Invivyd, Inc.'s (NASDAQ:IVVD) Price Is Right But Growth Is Lacking After Shares Rocket 31% - simplywall.st
What’s the recovery path for long term holders of Invivyd Inc.Quarterly Trade Review & AI Forecast for Swing Trade Picks - newser.com
Real time pattern detection on Invivyd Inc. stockMarket Risk Report & Real-Time Buy Signal Alerts - newser.com
Candlestick signals on Invivyd Inc. stock todayDollar Strength & Safe Investment Capital Preservation Plans - newser.com
Can a trend reversal in Invivyd Inc. lead to recoveryMarket Growth Review & Weekly Watchlist for Hot Stocks - newser.com
How Invivyd Inc. stock performs in interest rate cyclesWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
Using Python tools to backtest Invivyd Inc. strategies2025 Top Decliners & Low Risk Growth Stock Ideas - newser.com
How to forecast Invivyd Inc. trends using time seriesJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Will Invivyd Inc. stock gain from strong economyPortfolio Risk Summary & Growth Focused Stock Reports - newser.com
What Fibonacci levels say about Invivyd Inc. reboundWeekly Gains Report & Free Fast Gain Swing Trade Alerts - newser.com
Is Invivyd Inc. stock in correction or buying zoneAnalyst Downgrade & Entry Point Confirmation Signals - newser.com
How to use Fibonacci retracement on Invivyd Inc.Market Growth Review & Free Community Consensus Stock Picks - newser.com
Cantor Fitzgerald Estimates Invivyd FY2025 Earnings - MarketBeat
Detecting support and resistance levels for Invivyd Inc.Quarterly Portfolio Review & Reliable Volume Spike Trade Alerts - newser.com
How supply chain issues affect Invivyd Inc. stockInsider Buying & Accurate Entry/Exit Alerts - newser.com
Ranking Invivyd Inc. among high performing stocks via toolsEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
A Look at Invivyd’s (IVVD) Valuation Following FDA Clearance for Late-Stage COVID-19 Antibody Trial - simplywall.st
What candlestick patterns are forming on Invivyd Inc.July 2025 Momentum & Short-Term High Return Strategies - newser.com
Invivyd (IVVD) Is Up 34.4% After FDA Clears Late-Stage COVID Antibody Program—What’s Changed - Yahoo Finance
Invivyd (NASDAQ:IVVD) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
When is the best time to exit Invivyd Inc.Weekly Profit Analysis & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Invivyd Inc. rally from current levelsPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
Multi asset correlation models including Invivyd Inc.2025 Macro Impact & Weekly Watchlist for Consistent Profits - newser.com
Are Investors Undervaluing Invivyd, Inc. (NASDAQ:IVVD) By 31%? - 富途牛牛
Invivyd (IVVD) Is Up 26.8% After FDA Clears Phase 3 Trials for COVID Antibody Candidate - simplywall.st
Invivyd (IVVD): Assessing Valuation After FDA Clears Phase 3 COVID-19 Antibody Trial - Yahoo Finance
D. Boral Capital Maintains Invivyd (IVVD) Buy Recommendation - Nasdaq
Invivyd receives FDA clearance for COVID antibody prevention trials By Investing.com - Investing.com Nigeria
D. Boral Capital Increases Invivyd (NASDAQ:IVVD) Price Target to $2.00 - MarketBeat
Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program - MarketScreener
New Haven biotech advances vaccine-alternative to prevent COVID - Hartford Business Journal
Invivyd stock soars after FDA clears IND for COVID antibody candidate - Investing.com
Cantor Fitzgerald Initiates Invivyd at Overweight With $10 Price Target - MarketScreener
This Commerce Bancshares Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug - MarketScreener
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Invivyd (NASDAQ:IVVD) Now Covered by Cantor Fitzgerald - MarketBeat
Invivyd announces IND clearance, alignment with FDA on VYD2311 program - TipRanks
Invivyd’s VYD2311 Receives FDA Clearance for Trials - TipRanks
Invivyd receives FDA clearance for COVID antibody prevention trials - Investing.com
Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311 - MarketScreener
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - The Manila Times
Invivyd Announces Upcoming Phase 3 Clinical Trials for VYD2311, a Novel COVID Prevention Therapy - Quiver Quantitative
What to do if you’re stuck in Invivyd Inc.Exit Point & Fast Exit and Entry Trade Guides - newser.com
Earnings visualization tools for Invivyd Inc.July 2025 Intraday Action & Daily Profit Focused Screening - newser.com
Why retail investors pile into Invivyd Inc. stockJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Finanzdaten der Invivyd Inc-Aktie (IVVD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Invivyd Inc-Aktie (IVVD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lee Timothy Edward | Chief Commercial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
88,987 |
| Duke William E. | Chief Financial Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Duke William E. | Chief Financial Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Green Julie | Chief Human Resources Officer |
Aug 19 '25 |
Sale |
0.57 |
29,643 |
16,796 |
49,344 |
| Green Julie | Chief Human Resources Officer |
Aug 18 '25 |
Sale |
0.65 |
20,013 |
13,012 |
78,987 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 19 '25 |
Sale |
0.57 |
49,402 |
27,991 |
84,446 |
| Andersen Jill | Chief Legal Officer, Secretary |
Aug 18 '25 |
Sale |
0.65 |
33,352 |
21,685 |
133,848 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 19 '25 |
Sale |
0.57 |
27,420 |
15,536 |
53,068 |
| Allen Robert D. III | Chief Scientific Officer |
Aug 18 '25 |
Sale |
0.65 |
18,512 |
12,037 |
80,488 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):